Drug Trial Radar · NCT03687632
ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects
Last checked: Nov 19, 2026Latest source record: Aug 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Jun 10, 2019
Primary completion
Aug 18, 2020
Study completion Aug 25, 2020
Sponsor
- Lead sponsor
- Noveome Biotherapeutics, formerly StemnionIndustry
- Sponsor type
- Industry
- First posted
- Sep 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary aim of the study is to evaluate the clinical response of ST266 treated subjects with persistent corneal epithelial defects during 28 days of therapy. The secondary endpoint is the response rate within 14 days of treatment.
Conditions
- Persistent Corneal Epithelial Defect
Interventions
ST266Biological
1X ST266 applied in a dose of one drop (30-50 µL) in the study eye for 28 days (112 doses total will be administered).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with complete healing of PED during 28 days of treatment startingTime frame: 28 days
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Price Vision Group
Indianapolis, Indiana
Cincinnati Eye Institute
Edgewood, Kentucky
University of Maryland
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Cleveland Clinic
Cleveland, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Univesity of Pittsburgh
Pittsburgh, Pennsylvania
University of West Virginia
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.